More information on this family may be found on the IUPHAR-DB family and introduction pages.
The 5-HT3 receptor [nomenclature as agreed by the NC-IUPHAR Subcommittee on 5-hydroxytryptamine (serotonin) receptors [16]] is a ligand-gated ion channel of the Cys-loop family that includes the nicotinic acetylcholine, GABAA and strychnine-sensitive glycine receptors. The receptor exists as a pentamer of 4TM subunits that form an intrinsic cation selective channel [2]. Five human 5-HT3 receptor subunits have been cloned and homo-oligomeric assemblies of 5-HT3A and hetero-oligomeric assemblies of 5-HT3A and 5-HT3B subunits have been characterised in detail. The 5-HT3C (ENSG00000178084), 5-HT3D (ENSG00000186090) and 5-HT3E (ENSG00000186038) subunits [22,32], like the 5-HT3B subunit, do not form functional homomers, but are reported to assemble with the 5-HT3A subunit to influence its functional expression rather than pharmacological profile [13,34,49]. 5-HT3A, -C, -D, and -E subunits also interact with the chaperone RIC-3 which predominantly enhances the surface expression of homomeric 5-HT3A receptor [49]. The co-expression of 5-HT3A and 5-HT3C-E subunits has been demonstrated in human colon [21]. A recombinant hetero-oligomeric 5-HT3AB receptor has been reported to contain two copies of the 5-HT3A subunit and three copies of the 5-HT3B subunit in the order B-B-A-B-A [3], but this is inconsistent with recent reports which show at least one A-A interface [25,47]. The 5-HT3B subunit imparts distinctive biophysical properties upon hetero-oligomeric 5-HT3AB versus homo-oligomeric 5-HT3A recombinant receptors [8,10-11,19,23,37,40], influences the potency of channel blockers, but generally has only a modest effect upon the apparent affinity of agonists, or the affinity of antagonists ([5], but see [7,9-10]) which may be explained by the orthosteric binding site residing at an interface formed between 5-HT3A subunits [25,47]. However, 5-HT3A and 5-HT3AB receptors differ in their allosteric regulation by some general anaesthetic agents, small alcohols and indoles [17,38-39]. The potential diversity of 5-HT3receptors is increased by alternative splicing of the genes HTR3A and E [6,14,31,33-34]. In addition, the use of tissue-specific promoters driving expression from different transcriptional start sites has been reported for the HTR3A, HTR3B, HTR3D and HTR3E genes, which could result in 5-HT3 subunits harbouring different N-termini [19,31,48]. To date, inclusion of the 5-HT3A subunit appears imperative for 5-HT3 receptor function.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
Barnes NM, Hales TG, Lummis SC, Peters JA. (2008) The 5-HT(3) receptor - the relationship between structure and function. Neuropharmacology., Epub ahead of print. [PMID:18761359]
Chameau, P; van Hooft, JA. (2006) Serotonin 5-HT(3) receptors in the central nervous system. Cell Tissue Res., 326 (2): 573-81. [PMID:16826372]
Costall, B; Naylor, RJ. (2004) 5-HT3 receptors. Curr. Drug Targets CNS Neurol. Disord., 3 (1): 27-37. [PMID:14965242]
Engleman, EA; Rodd, ZA; Bell, RL; Murphy, JM. (2008) The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy. CNS Neurol Disord Drug Targets, 7 (5): 454-67. [PMID:19128203]
Hoyer, D; Clarke, DE; Fozard, JR; Hartig, PR; Martin, GR; Mylecharane, EJ; Saxena, PR; Humphrey, PP. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46 (2): 157-203. [PMID:7938165]
Jensen, AA; Davies, PA; Bräuner-Osborne, H; Krzywkowski, K. (2008) 3B but which 3B and that's just one of the questions: the heterogeneity of human 5-HT3 receptors. Trends Pharmacol. Sci., 29 (9): 437-44. [PMID:18597859]
Machu, TK. (2011) Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol. Ther., 130 (3): 338-47. [PMID:21356241]
Modica, MN; Pittalà, V; Romeo, G; Salerno, L; Siracusa, MA. (2010) Serotonin 5-HT3 and 5-HT4 ligands: an update of medicinal chemistry research in the last few years. Curr. Med. Chem., 17 (4): 334-62. [PMID:20015043]
Niesler, B. (2011) 5-HT(3) receptors: potential of individual isoforms for personalised therapy. Curr Opin Pharmacol, 11 (1): 81-6. [PMID:21345729]
Niesler, B; Kapeller, J; Hammer, C; Rappold, G. (2008) Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics, 9 (5): 501-4. [PMID:18466097]
Parker, RM; Bentley, KR; Barnes, NM. (1996) Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents. Trends Pharmacol. Sci., 17 (3): 95-9. [PMID:8936343]
Peters, JA; Hales, TG; Lambert, JJ. (2005) Molecular determinants of single-channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT3 receptor. Trends Pharmacol. Sci., 26 (11): 587-94. [PMID:16194573]
Thompson, AJ; Lester, HA; Lummis, SC. (2010) The structural basis of function in Cys-loop receptors. Q. Rev. Biophys., 43 (4): 449-99. [PMID:20849671]
Thompson, AJ; Lummis, SC. (2006) 5-HT3 receptors. Curr. Pharm. Des., 12 (28): 3615-30. [PMID:17073663]
Thompson, AJ; Lummis, SC. (2007) The 5-HT3 receptor as a therapeutic target. Expert Opin. Ther. Targets, 11 (4): 527-40. [PMID:17373882]
Walstab, J; Rappold, G; Niesler, B. (2010) 5-HT(3) receptors: role in disease and target of drugs. Pharmacol. Ther., 128 (1): 146-69. [PMID:20621123]
Yaakob, N; Malone, DT; Exintaris, B; Irving, HR. (2011) Heterogeneity amongst 5-HT₃ receptor subunits: is this significant?. Curr. Mol. Med., 11 (1): 57-68. [PMID:21189117]
1. Abi-Dargham, A; Laruelle, M; Wong, DT; Robertson, DW; Weinberger, DR; Kleinman, JE. (1993) Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J. Neurochem., 60 (2): 730-7. [PMID:8419547]
2. Barnes NM, Hales TG, Lummis SC, Peters JA. (2008) The 5-HT(3) receptor - the relationship between structure and function. Neuropharmacology., Epub ahead of print. [PMID:18761359]
3. Barrera, NP; Herbert, P; Henderson, RM; Martin, IL; Edwardson, JM. (2005) Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc. Natl. Acad. Sci. U.S.A., 102 (35): 12595-600. [PMID:16116092]
4. Belelli, D; Balcarek, JM; Hope, AG; Peters, JA; Lambert, JJ; Blackburn, TP. (1995) Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol. Pharmacol., 48 (6): 1054-62. [PMID:8848005]
5. Brady, CA; Stanford, IM; Ali, I; Lin, L; Williams, JM; Dubin, AE; Hope, AG; Barnes, NM. (2001) Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology, 41 (2): 282-4. [PMID:11489465]
6. Brüss, M; Barann, M; Hayer-Zillgen, M; Eucker, T; Göthert, M; Bönisch, H. (2000) Modified 5-HT3A receptor function by co-expression of alternatively spliced human 5-HT3A receptor isoforms. Naunyn Schmiedebergs Arch. Pharmacol., 362 (4-5): 392-401. [PMID:11111833]
7. Das, P; Dillon, GH. (2003) The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor. Brain Res. Mol. Brain Res., 119 (2): 207-12. [PMID:14625088]
8. Davies, PA; Pistis, M; Hanna, MC; Peters, JA; Lambert, JJ; Hales, TG; Kirkness, EF. (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature, 397 (6717): 359-63. [PMID:9950429]
9. Deeb, TZ; Sharp, D; Hales, TG. (2009) Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol. Pharmacol., 75 (4): 908-17. [PMID:19131665]
10. Dubin, AE; Huvar, R; D'Andrea, MR; Pyati, J; Zhu, JY; Joy, KC; Wilson, SJ; Galindo, JE; Glass, CA; Luo, L; Jackson, MR; Lovenberg, TW; Erlander, MG. (1999) The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J. Biol. Chem., 274 (43): 30799-810. [PMID:10521471]
11. Hanna, MC; Davies, PA; Hales, TG; Kirkness, EF. (2000) Evidence for expression of heteromeric serotonin 5-HT(3) receptors in rodents. J. Neurochem., 75 (1): 240-7. [PMID:10854267]
12. Hirata, T; Keto, Y; Funatsu, T; Akuzawa, S; Sasamata, M. (2007) Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J. Pharmacol. Sci., 104 (3): 263-73. [PMID:17652911]
13. Holbrook, JD; Gill, CH; Zebda, N; Spencer, JP; Leyland, R; Rance, KH; Trinh, H; Balmer, G; Kelly, FM; Yusaf, SP; Courtenay, N; Luck, J; Rhodes, A; Modha, S; Moore, SE; Sanger, GJ; Gunthorpe, MJ. (2009) Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J. Neurochem., 108 (2): 384-96. [PMID:19012743]
14. Hope, AG; Downie, DL; Sutherland, L; Lambert, JJ; Peters, JA; Burchell, B. (1993) Cloning and functional expression of an apparent splice variant of the murine 5-HT3 receptor A subunit. Eur. J. Pharmacol., 245 (2): 187-92. [PMID:7683998]
15. Hope, AG; Peters, JA; Brown, AM; Lambert, JJ; Blackburn, TP. (1996) Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells. Br. J. Pharmacol., 118 (5): 1237-45. [PMID:8818349]
16. Hoyer, D; Clarke, DE; Fozard, JR; Hartig, PR; Martin, GR; Mylecharane, EJ; Saxena, PR; Humphrey, PP. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46 (2): 157-203. [PMID:7938165]
17. Hu, XQ; Peoples, RW. (2008) The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor. J. Biol. Chem., 283 (11): 6826-31. [PMID:18187416]
18. Isenberg, KE; Ukhun, IA; Holstad, SG; Jafri, S; Uchida, U; Zorumski, CF; Yang, J. (1993) Partial cDNA cloning and NGF regulation of a rat 5-HT3 receptor subunit. Neuroreport, 5 (2): 121-4. [PMID:7509203]
19. Jensen, AA; Davies, PA; Bräuner-Osborne, H; Krzywkowski, K. (2008) 3B but which 3B and that's just one of the questions: the heterogeneity of human 5-HT3 receptors. Trends Pharmacol. Sci., 29 (9): 437-44. [PMID:18597859]
20. Jensen, TN; Nielsen, J; Frederiksen, K; Ebert, B. (2006) Molecular cloning and pharmacological characterization of serotonin 5-HT(3A) receptor subtype in dog. Eur. J. Pharmacol., 538 (1-3): 23-31. [PMID:16647053]
21. Kapeller, J; Möller, D; Lasitschka, F; Autschbach, F; Hovius, R; Rappold, G; Brüss, M; Gershon, MD; Niesler, B. (2011) Serotonin receptor diversity in the human colon: Expression of serotonin type 3 receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. J. Comp. Neurol., 519 (3): 420-32. [PMID:21192076]
22. Karnovsky, AM; Gotow, LF; McKinley, DD; Piechan, JL; Ruble, CL; Mills, CJ; Schellin, KA; Slightom, JL; Fitzgerald, LR; Benjamin, CW; Roberds, SL. (2003) A cluster of novel serotonin receptor 3-like genes on human chromosome 3. Gene, 319: 137-48. [PMID:14597179]
23. Kelley, SP; Dunlop, JI; Kirkness, EF; Lambert, JJ; Peters, JA. (2003) A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. Nature, 424 (6946): 321-4. [PMID:12867984]
24. Lankiewicz, S; Lobitz, N; Wetzel, CH; Rupprecht, R; Gisselmann, G; Hatt, H. (1998) Molecular cloning, functional expression, and pharmacological characterization of 5-hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. Mol. Pharmacol., 53 (2): 202-12. [PMID:9463477]
25. Lochner, M; Lummis, SC. (2010) Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor. Biophys. J., 98 (8): 1494-502. [PMID:20409468]
26. Lummis, SC; Thompson, AJ; Bencherif, M; Lester, HA. (2011) Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor. J. Pharmacol. Exp. Ther., 339 (1): 125-31. [PMID:21775477]
27. Maricq, AV; Peterson, AS; Brake, AJ; Myers, RM; Julius, D. (1991) Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science, 254 (5030): 432-7. [PMID:1718042]
28. Miyake, A; Mochizuki, S; Takemoto, Y; Akuzawa, S. (1995) Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol. Pharmacol., 48 (3): 407-16. [PMID:7565620]
29. Mochizuki, S; Miyake, A; Furuichi, K. (1999) Identification of a domain affecting agonist potency of meta-chlorophenylbiguanide in 5-HT3 receptors. Eur. J. Pharmacol., 369 (1): 125-32. [PMID:10204690]
30. Mochizuki, S; Watanabe, T; Miyake, A; Saito, M; Furuichi, K. (2000) Cloning, expression, and characterization of ferret 5-HT(3) receptor subunit. Eur. J. Pharmacol., 399 (2-3): 97-106. [PMID:10884508]
31. Niesler, B. (2011) 5-HT(3) receptors: potential of individual isoforms for personalised therapy. Curr Opin Pharmacol, 11 (1): 81-6. [PMID:21345729]
32. Niesler, B; Frank, B; Kapeller, J; Rappold, GA. (2003) Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene, 310: 101-11. [PMID:12801637]
33. Niesler, B; Kapeller, J; Hammer, C; Rappold, G. (2008) Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics, 9 (5): 501-4. [PMID:18466097]
34. Niesler, B; Walstab, J; Combrink, S; Möller, D; Kapeller, J; Rietdorf, J; Bönisch, H; Göthert, M; Rappold, G; Brüss, M. (2007) Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol. Pharmacol., 72 (1): 8-17. [PMID:17392525]
35. Parker, RM; Barnes, JM; Ge, J; Barber, PC; Barnes, NM. (1996) Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J. Neurol. Sci., 144 (1-2): 119-27. [PMID:8994113]
36. Parker, RM; Bentley, KR; Barnes, NM. (1996) Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents. Trends Pharmacol. Sci., 17 (3): 95-9. [PMID:8936343]
37. Peters, JA; Hales, TG; Lambert, JJ. (2005) Molecular determinants of single-channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT3 receptor. Trends Pharmacol. Sci., 26 (11): 587-94. [PMID:16194573]
38. Rüsch, D; Musset, B; Wulf, H; Schuster, A; Raines, DE. (2007) Subunit-dependent modulation of the 5-hydroxytryptamine type 3 receptor open-close equilibrium by n-alcohols. J. Pharmacol. Exp. Ther., 321 (3): 1069-74. [PMID:17360702]
39. Solt, K; Stevens, RJ; Davies, PA; Raines, DE. (2005) General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition. J. Pharmacol. Exp. Ther., 315 (2): 771-6. [PMID:16081679]
40. Stewart, A; Davies, PA; Kirkness, EF; Safa, P; Hales, TG. (2003) Introduction of the 5-HT3B subunit alters the functional properties of 5-HT3 receptors native to neuroblastoma cells. Neuropharmacology, 44 (2): 214-23. [PMID:12623220]
41. Sun, H; McCardy, EA; Machu, TK; Blanton, MP. (1999) Characterization of interaction of 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester with Torpedo californica nicotinic acetylcholine receptor and 5-hydroxytryptamine3 receptor. J. Pharmacol. Exp. Ther., 290 (1): 129-35. [PMID:10381768]
42. Thompson, AJ; Duke, RK; Lummis, SC. (2011) Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol. Pharmacol., 80 (1): 183-90. [PMID:21505038]
43. Thompson, AJ; Jarvis, GE; Duke, RK; Johnston, GA; Lummis, SC. (2011) Ginkgolide B and bilobalide block the pore of the 5-HT(3) receptor at a location that overlaps the picrotoxin binding site. Neuropharmacology, 60 (2-3): 488-95. [PMID:21059362]
44. Thompson, AJ; Lummis, SC. (2006) 5-HT3 receptors. Curr. Pharm. Des., 12 (28): 3615-30. [PMID:17073663]
45. Thompson, AJ; Lummis, SC. (2007) The 5-HT3 receptor as a therapeutic target. Expert Opin. Ther. Targets, 11 (4): 527-40. [PMID:17373882]
46. Thompson, AJ; Lummis, SC. (2008) Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors. Br. J. Pharmacol., 153 (8): 1686-96. [PMID:18311193]
47. Thompson, AJ; Price, KL; Lummis, SC. (2011) Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT3AB receptors. J. Physiol. (Lond.), 589 (Pt 17): 4243-57. [PMID:21708905]
48. Tzvetkov, MV; Meineke, C; Oetjen, E; Hirsch-Ernst, K; Brockmöller, J. (2007) Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene, 386 (1-2): 52-62. [PMID:17010535]
49. Walstab, J; Hammer, C; Lasitschka, F; Möller, D; Connolly, CN; Rappold, G; Brüss, M; Bönisch, H; Niesler, B. (2010) RIC-3 exclusively enhances the surface expression of human homomeric 5-hydroxytryptamine type 3A (5-HT3A) receptors despite direct interactions with 5-HT3A, -C, -D, and -E subunits. J. Biol. Chem., 285 (35): 26956-65. [PMID:20522555]
50. Walstab, J; Rappold, G; Niesler, B. (2010) 5-HT(3) receptors: role in disease and target of drugs. Pharmacol. Ther., 128 (1): 146-69. [PMID:20621123]
|
@GuidetoPHARM Like us on Facebook Privacy and Cookie Policy |


Quantitative data in the table refer to homo-oligomeric assemblies of the human 5-HT3A subunit, or the receptor native to human tissues. Significant changes introduced by co-expression of the 5-HT3B subunit are indicated in parenthesis. Although not a selective antagonist, methadone displays multimodal and subunit-dependent antagonism of 5-HT3 receptors [9]. Similarly, TMB-8, diltiazem, picrotoxin, bilobalide and ginkgolide B are not selective for 5-HT3 receptors (e.g.[43]). The anti-malarial drugs mefloquine and quinine exert a modestly more potent block of 5-HT3A versus 5-HT3AB receptor-mediated responses [46]. Known better as a partial agonist of nicotinic acetylcholine α4β2 receptors, varenicline is also an agonist of the 5-HT3A receptor [26]. Human [4,28], rat [18], mouse [27], guinea-pig [24] ferret [30] and canine [20] orthologues of the 5-HT3A receptor subunit have been cloned that exhibit intraspecies variations in receptor pharmacology. Notably, most ligands display significantly reduced affinities at the guinea-pig 5-HT3 receptor in comparison with other species. In addition to the agents listed in the table, native and recombinant 5-HT3 receptors are subject to allosteric modulation by extracellular divalent cations, alcohols, several general anaesthetics and 5-hydroxy- and halide-substituted indoles (see reviews [36,44-45,50]).